<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725361</url>
  </required_header>
  <id_info>
    <org_study_id>SU-07222008-1265</org_study_id>
    <secondary_id>IRB Protocol # 14409</secondary_id>
    <nct_id>NCT00725361</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy of Ambrisentan in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      This is a research study of an investigational drug called ambrisentan (Letairis) in the
      treatment and prevention of digital ulcers in patients with systemic sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ambrisentan is an endothelin blocker approved for the treatment of pulmonary arterial
      hypertension. Patients with systemic sclerosis can have damage to their blood vessels,
      resulting in increased levels of endothelin in their bloodstream that then causes decreased
      blood flow to the digits. This can result in very painful digital ulcers. We hope to learn
      whether blocking the action of endothelin with ambrisentan will be helpful in the treatment
      and prevention of digital ulcers in patients with systemic sclerosis. This therapy is not
      approved for the treatment of systemic sclerosis, but this study will help us learn whether
      ambrisentan is safe and effective in the treatment and prevention of digital ulcers in
      patients with systemic sclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New Digital Ulcers (DU) 4 Weeks Prior to Week 24</measure>
    <time_frame>4 weeks prior to week 24</time_frame>
    <description>The number of new digital ulcers (DU) that have developed in the preceding 4 weeks assessed at week 24 from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New DU 4 Weeks Prior to Week 12</measure>
    <time_frame>4 weeks prior to week 12</time_frame>
    <description>The number of new DU that have developed in the preceding 4 weeks assessed at week 12 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Experiencing Complete (Total Reepithelialization) Healing of All Baseline DU at Week 12.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Experiencing Complete Healing of &gt; 50% of the Number of Baseline DU at Week 12.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Scleroderma Health Assessment Questionnaire (SHAQ) at Week 24 Compared With Baseline.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Range is 0-3 with 0 meaning the least amount of disability and 3 the greatest of disability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>n Ulcer</condition>
  <condition>Scleroderma, Systemic</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ambrisentan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of limited or diffuse systemic sclerosis (SSc) according to American College
             of Rheumatology or LeRoy criteria

          -  Age greater than 18 years of age

          -  At least one digital ulcer located on the volar or lateral surface at or distal to the
             proximal interphalangeal joints

          -  At least one new DU that developed within 12 weeks prior to screening

          -  Vasodilator therapies, including calcium channel blockers, alpha-1-antagonists,
             ACE-inhibitors, nitroglycerin, and angiotensin receptor blockers, are permitted as
             long as the doses are stable for 2 weeks prior to screening and throughout the study

          -  Treatment with omeprazole or other proton pump inhibitors must be stable for 2 weeks
             prior to screening and throughout the study

        Exclusion Criteria:

          -  Patients with pulmonary arterial hypertension, NYHA Class III or IV

          -  Patients who are hemodynamically unstable, or have acute renal, cardiac or pulmonary
             failure

          -  Concurrent malignancy except non-melanoma skin cancers

          -  Patients who have required systemic antibiotics for infected digital ulcers within 2
             weeks of screening

          -  Patients receiving phosphodiesterase-5 inhibitors, endothelin receptor antagonists, or
             prostanoids within 4 weeks of screening

          -  Patients receiving cyclosporine within 6 weeks of screening

          -  Patients who have participated in any investigational study within 30 days of
             screening

          -  Pregnant or nursing women

          -  Patients with a history of drug or alcohol abuse within 6 months of screening

          -  History of hepatitis B, hepatitis C, or HIV infection

          -  Any medical condition that, in the opinion of the investigator, might interfere with
             the subject's participation in the study or poses an added risk for the subject

          -  Inability to comply with study and follow-up procedures

          -  Transaminase elevation &gt; 3X the upper limit of normal at screening

          -  Hemoglobin less than 8.5 g/dL

          -  Platelet count less than 100 X 109/L

          -  White blood cell count less than 3.0 X 109/L

          -  Serum creatinine less than 2.0 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorinda S Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <results_first_submitted>December 20, 2016</results_first_submitted>
  <results_first_submitted_qc>January 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2017</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Lorinda S Chung</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ambrisentan</title>
          <description>5 mg orally daily X 4 weeks then 10 mg daily as tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Ambrisentan
Ambrisentan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of total baseline digital ulcers</title>
          <units>digital ulcers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean diameter of baseline digital ulcers</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>New Digital Ulcers (DU) 4 Weeks Prior to Week 24</title>
        <description>The number of new digital ulcers (DU) that have developed in the preceding 4 weeks assessed at week 24 from baseline.</description>
        <time_frame>4 weeks prior to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Ambrisentan
Ambrisentan</description>
          </group>
        </group_list>
        <measure>
          <title>New Digital Ulcers (DU) 4 Weeks Prior to Week 24</title>
          <description>The number of new digital ulcers (DU) that have developed in the preceding 4 weeks assessed at week 24 from baseline.</description>
          <units>new digital ulcers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New DU 4 Weeks Prior to Week 12</title>
        <description>The number of new DU that have developed in the preceding 4 weeks assessed at week 12 from baseline.</description>
        <time_frame>4 weeks prior to week 12</time_frame>
        <population>At 12 weeks only 1 patient had withdrawn from the study and 19 remained in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Ambrisentan
Ambrisentan</description>
          </group>
        </group_list>
        <measure>
          <title>New DU 4 Weeks Prior to Week 12</title>
          <description>The number of new DU that have developed in the preceding 4 weeks assessed at week 12 from baseline.</description>
          <population>At 12 weeks only 1 patient had withdrawn from the study and 19 remained in the study.</population>
          <units>new digital ulcers</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Experiencing Complete (Total Reepithelialization) Healing of All Baseline DU at Week 12.</title>
        <time_frame>12 weeks</time_frame>
        <population>At 12 weeks only 1 patient had withdrawn from the study and 19 remained in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Ambrisentan
Ambrisentan</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Experiencing Complete (Total Reepithelialization) Healing of All Baseline DU at Week 12.</title>
          <population>At 12 weeks only 1 patient had withdrawn from the study and 19 remained in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Experiencing Complete Healing of &gt; 50% of the Number of Baseline DU at Week 12.</title>
        <time_frame>12 weeks</time_frame>
        <population>At 12 weeks only 1 patient had withdrawn from the study and 19 remained in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Ambrisentan
Ambrisentan</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Experiencing Complete Healing of &gt; 50% of the Number of Baseline DU at Week 12.</title>
          <population>At 12 weeks only 1 patient had withdrawn from the study and 19 remained in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Scleroderma Health Assessment Questionnaire (SHAQ) at Week 24 Compared With Baseline.</title>
        <description>Range is 0-3 with 0 meaning the least amount of disability and 3 the greatest of disability.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Ambrisentan
Ambrisentan</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Scleroderma Health Assessment Questionnaire (SHAQ) at Week 24 Compared With Baseline.</title>
          <description>Range is 0-3 with 0 meaning the least amount of disability and 3 the greatest of disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening through week 28 for a total of 32 weeks of data collection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Ambrisentan
Ambrisentan</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Raynaud attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected digital ulcer</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lorinda Chung</name_or_title>
      <organization>StanfordU</organization>
      <phone>650-736-0727</phone>
      <email>shauwei@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

